Clinical Trial

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a…

6 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on…

6 months ago

PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company…

6 months ago

MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight

MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with…

6 months ago

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start…

6 months ago

Starton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)

PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with…

6 months ago

Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome

First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their…

6 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for…

6 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request…

6 months ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025…

6 months ago